Justice Angela 4

4 · TCR2 THERAPEUTICS INC. · Filed Dec 5, 2022

Form 4

Period: 2022-12-01

Chief People Officer

Transactions

Exercise/Conversion
Restricted Stock Unit
2022-12-01+2,840→ 1,050 total
→ Common Stock (2,840 underlying)
Exercise/Conversion
Common Stock
2022-12-01+59,576→ 69,269 total
Sale
Common Stock
2022-12-02$1.39/sh−2,273$3,162→ 66,996 total
Exercise/Conversion
Restricted Stock Unit
2022-12-01+50,889→ 13,527 total
→ Common Stock (50,889 underlying)
Exercise/Conversion
Restricted Stock Unit
2022-12-01+5,847→ 6,336 total
→ Common Stock (5,847 underlying)

Holdings

Footnotes (6)

[F1]Represents the the aggregate number of common stock converted from restricted stock units granted to the reporting person on 11/17/2022 pursuant to the issuer's offer to exchange eligible options for new restricted stock units program.
[F2]Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.
[F3]The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.
[F4]79% of these restricted stock units vested on December 1, 2022 and the remaining 21% will vest on December 1, 2023.
[F5]73% of these restricted stock units vested on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024.
[F6]48% of these restricted stock units vested on December 1, 2022, 25% will vest on December 1, 2023, 25% will vest on December 1, 2024 and the remaining 2% will vest on December 1, 2025.

Documents

1 file